BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33289072)

  • 1. FGF23, Frailty, and Falls in SPRINT.
    Jovanovich A; Ginsberg C; You Z; Katz R; Ambrosius WT; Berlowitz D; Cheung AK; Cho M; Lee AK; Punzi H; Rehman S; Roumie C; Supiano MA; Wright CB; Shlipak M; Ix JH; Chonchol M
    J Am Geriatr Soc; 2021 Feb; 69(2):467-473. PubMed ID: 33289072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
    Potok OA; Ix JH; Shlipak MG; Katz R; Hawfield AT; Rocco MV; Ambrosius WT; Cho ME; Pajewski NM; Rastogi A; Rifkin DE
    Am J Kidney Dis; 2020 Dec; 76(6):765-774. PubMed ID: 32682697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
    Ginsberg C; Craven TE; Chonchol MB; Cheung AK; Sarnak MJ; Ambrosius WT; Killeen AA; Raphael KL; Bhatt UY; Chen J; Chertow GM; Freedman BI; Oparil S; Papademetriou V; Wall BM; Wright CB; Ix JH; Shlipak MG;
    Clin J Am Soc Nephrol; 2018 Dec; 13(12):1816-1824. PubMed ID: 30425104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
    Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
    Isakova T; Cai X; Lee J; Katz R; Cauley JA; Fried LF; Hoofnagle AN; Satterfield S; Harris TB; Shlipak MG; Sarnak MJ; Ix JH;
    J Bone Miner Res; 2016 Apr; 31(4):742-8. PubMed ID: 26590361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and incident CKD in type 2 diabetes.
    Isakova T; Craven TE; Lee J; Scialla JJ; Xie H; Wahl P; Marcovina SM; Byington RP; Wolf M
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):29-38. PubMed ID: 25343949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
    Westerberg PA; Tivesten Å; Karlsson MK; Mellström D; Orwoll E; Ohlsson C; Larsson TE; Linde T; Ljunggren Ö
    BMC Nephrol; 2013 Apr; 14():85. PubMed ID: 23587028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
    Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
    Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Hodakowski A; Lee J; Leonard M; Ricardo A; Chen J; Hamm L; Sondheimer J; Dobre M; David V; Yang W; Go A; Kusek JW; Feldman H; Wolf M; Isakova T;
    Clin J Am Soc Nephrol; 2017 Nov; 12(11):1795-1803. PubMed ID: 28784656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M;
    JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women.
    Semba RD; Fink JC; Sun K; Cappola AR; Dalal M; Crasto C; Ferrucci L; Fried LP
    Clin J Am Soc Nephrol; 2012 Jan; 7(1):85-91. PubMed ID: 22076875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.
    Lundberg S; Qureshi AR; Olivecrona S; Gunnarsson I; Jacobson SH; Larsson TE
    Clin J Am Soc Nephrol; 2012 May; 7(5):727-34. PubMed ID: 22383747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.